Drug Profile
SGM 1019
Alternative Names: SGM-1019Latest Information Update: 13 Dec 2022
Price :
$50
*
At a glance
- Originator Evotec AG
- Developer Second Genome
- Class Anti-inflammatories; Antifibrotics; Hepatoprotectants; Small molecules
- Mechanism of Action Gastrointestinal microbiome modulators; Inflammasome inhibitors; Purinergic P2X7 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammatory bowel diseases; Non-alcoholic steatohepatitis
Most Recent Events
- 13 Dec 2022 Discontinued - Phase-I for Inflammatory bowel diseases (In volunteers) in USA (PO)
- 13 Dec 2022 Discontinued - Phase-II for Non-alcoholic steatohepatitis in USA (PO)
- 30 Nov 2022 No development reported - Phase-II for Non-alcoholic steatohepatitis in USA (PO)